• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease.

作者信息

Iwama Itaru, Yoshida Masashi, Miyazawa Ayako, Hara Tomoko, Nambu Ryusuke

机构信息

Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.

出版信息

Inflamm Bowel Dis. 2024 Jul 3;30(7):1220-1222. doi: 10.1093/ibd/izae078.

DOI:10.1093/ibd/izae078
PMID:38588461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11219474/
Abstract
摘要

相似文献

1
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease.优特克单抗可使极早发型炎症性肠病实现长期临床缓解且安全性良好。
Inflamm Bowel Dis. 2024 Jul 3;30(7):1220-1222. doi: 10.1093/ibd/izae078.
2
Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.日本一家三级儿童医院中用于儿童和青少年炎症性肠病的优特克单抗。
J Gastroenterol Hepatol. 2021 Jan;36(1):125-130. doi: 10.1111/jgh.15128. Epub 2020 Jun 29.
3
Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study.维多珠单抗和优特克单抗治疗儿童期起病的炎症性肠病的疗效：一项真实世界多中心研究。
J Pediatr Gastroenterol Nutr. 2025 Jan;80(1):113-123. doi: 10.1002/jpn3.12384. Epub 2024 Oct 16.
4
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.乌司奴单抗治疗儿童炎症性肠病的有效性和安全性：系统评价。
Paediatr Drugs. 2023 Sep;25(5):499-513. doi: 10.1007/s40272-023-00586-7. Epub 2023 Aug 1.
5
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.系统评价和荟萃分析：血清乌司奴单抗浓度与炎症性肠病治疗反应的关系。
Inflamm Bowel Dis. 2024 Apr 3;30(4):660-670. doi: 10.1093/ibd/izad065.
6
Ustekinumab is safe and effective in pediatric patients with Crohn's disease.乌司奴单抗对克罗恩病儿科患者安全有效。
J Pediatr Gastroenterol Nutr. 2025 Apr;80(4):653-663. doi: 10.1002/jpn3.12452. Epub 2025 Jan 31.
7
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.抗TNF、维多珠单抗或乌司奴单抗双重生物疗法治疗炎症性肠病：一项汇总分析的系统评价
Scand J Gastroenterol. 2019 Apr;54(4):407-413. doi: 10.1080/00365521.2019.1597159. Epub 2019 Apr 4.
8
Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.不同维持期乌司奴单抗给药间隔治疗炎症性肠病的疗效和安全性的比较：系统评价和荟萃分析。
Eur J Gastroenterol Hepatol. 2024 Apr 1;36(4):359-370. doi: 10.1097/MEG.0000000000002718. Epub 2024 Feb 16.
9
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.在接受维得利珠单抗或乌司奴单抗治疗的炎症性肠病患者中，联合治疗并未提高临床或内镜缓解率。
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1366-1376.e2. doi: 10.1016/j.cgh.2020.07.012. Epub 2020 Jul 12.
10
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.优特克单抗治疗难治性炎症性肠病青年患者的临床疗效与安全性：一项回顾性队列研究。
Saudi J Gastroenterol. 2025 Mar 1;31(2):59-67. doi: 10.4103/sjg.sjg_7_24. Epub 2024 Apr 10.

引用本文的文献

1
What lies beneath: unveiling the umbilical bacterial flora in pediatric laparoscopic surgery.背后的真相：揭示小儿腹腔镜手术中的脐部细菌群落
Updates Surg. 2025 Aug 20. doi: 10.1007/s13304-025-02369-w.

本文引用的文献

1
Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease.抗肿瘤坏死因子 α 在极早发炎症性肠病中的疗效和安全性。
Inflamm Bowel Dis. 2024 Sep 3;30(9):1443-1453. doi: 10.1093/ibd/izad196.
2
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.乌司奴单抗治疗儿童炎症性肠病的有效性和安全性：系统评价。
Paediatr Drugs. 2023 Sep;25(5):499-513. doi: 10.1007/s40272-023-00586-7. Epub 2023 Aug 1.
3
Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.乌司奴单抗在儿童炎症性肠病中的应用：法国儿科 GETAID 的一项多中心研究。
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):763-770. doi: 10.1097/MPG.0000000000003758. Epub 2023 Mar 8.
4
Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.使用乌司奴单抗治疗药物难治性儿童克罗恩病的经验。
J Pediatr Gastroenterol Nutr. 2021 Nov 1;73(5):610-614. doi: 10.1097/MPG.0000000000003230.
5
Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.维多珠单抗治疗极早期炎症性肠病儿科患者的安全性和有效性
J Clin Med. 2021 Jul 5;10(13):2997. doi: 10.3390/jcm10132997.
6
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.乌司奴单抗治疗中重度活动期克罗恩病儿科患者的药代动力学、安全性和疗效：UniStar 研究的结果。
J Crohns Colitis. 2021 Nov 8;15(11):1931-1942. doi: 10.1093/ecco-jcc/jjab089.
7
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease.北美小儿胃肠病、肝病和营养学会关于极早发型炎症性肠病患者评估与管理的立场文件。
J Pediatr Gastroenterol Nutr. 2020 Mar;70(3):389-403. doi: 10.1097/MPG.0000000000002567.
8
Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study.英夫利昔单抗治疗非常早发型炎症性肠病的疗效和安全性：一项全国性比较回顾性研究。
United European Gastroenterol J. 2019 Jul;7(6):759-766. doi: 10.1177/2050640619847592. Epub 2019 Apr 25.
9
Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN.儿童炎症性肠病（IBD）亚型包括未分类IBD的诊断标准的制定与验证：欧洲儿科胃肠病、肝病和营养学会（ESPGHAN）儿科IBD波尔图组的多中心研究
J Crohns Colitis. 2017 Sep 1;11(9):1078-1084. doi: 10.1093/ecco-jcc/jjx053.